Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/12694
Title
Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases.
Author(s)
Richi, Patricia | Yuste, Jose Enrique ISCIII | Navío, Teresa | González-Hombrado, Laura | Salido, Marina | Thuissard-Vasallo, Israel | Jiménez-Díaz, Ana | Llorente, Jesús | Cebrián, Laura | Lojo, Leticia | Steiner, Martina | Cobo, Tatiana | Martín, María Dolores | García-Castro, Marta | Castro, Patricia | Muñoz-Fernández, Santiago
Date issued
2021-02-28
Citation
Vaccines (Basel). 2021 Feb 28;9(3):203.
Language
Inglés
Document type
journal article
Abstract
Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.
Subject
OPKA titers | PCV13 | PPV23 | anti-TNFα | Autoimmune inflammatory diseases | Biological therapy | Invasive pneumococcal disease | Rituximab | Tocilizumab
Online version
DOI
Collections